Pilot Study of the Spiration IBV™ System

Completed · Phase 2

Conditions studied: Emphysema

In brief

The Spiration Intra-Bronchial Valve is intended for use as a minimally invasive treatment for severe emphysema, using standard bronchoscopy. The valve is designed to limit airflow to a selected portion of the lung, producing a reduction in lung volume, which may improve pulmonary function in patients with emphysema.

Key facts

Study ID

NCT00145548

Run by

Olympus Corporation of the Americas

People needed

91

Starts

2003-12-01

Expected to finish

2007-08-01

Last updated by the study team

2011-06-16

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and Female subjects at least 18 years of age.
• Subject has severe, heterogeneous, predominantly upper lobe emphysema.
• Subject has ability to meet goals of, or currently satisfies goals of, a comprehensive pulmonary rehabilitation program.
• Subject has satisfied requirement for post-rehabilitation 6-minute walk of ≥ 140 m 6 and is able to complete 3 min unloaded pedaling in exercise tolerance test.
• Subject has abstained from cigarette smoking for 4 months, as confirmed by urine or serum cotinine test.
• Pulmonary function testing results demonstrate:
• FEV1 ≤ 45% predicted (≥ 15% predicted if age ≥ 70 years)
• TLC ≥ 100% predicted
• RV ≥ 150% predicted
• Arterial blood gas level indicates:
• PCO2 ≤ 50 mm Hg
• PO2 ≥ 45 mm Hg on room air (Denver criterion: PO2 ≥ 30 mm Hg)
• Subject has no co-existing major medical problems that would significantly increase the risk of the bronchoscopy procedure and is classified as ASA Class P4 or lower.
• If female, subject is not pregnant by a negative HCG pregnancy test within 7 days prior to the procedure.
• Subject has willingness to undertake the risk and morbidity associated with the required bronchoscopic procedures.
• Subject has willingness to participate in the study and complete the required follow-up visits.
• Subject has ability to provide informed consent.
• Subject has provided consent for treatment under this protocol and has granted access to relevant medical records to the sponsor, the Principal Investigator, the institution, the IRB and the FDA pertaining to their current lung disease condition, evaluation process, and the surgical procedure.

You may not qualify if…

• Patients with FEV1< 20% predicted and either homogeneous emphysema or DLCO < 20%. 3
• Subject is unable to provide informed consent.
• Subject is not an appropriate candidate for, or unable to tolerate, flexible bronchoscopy procedures.
• Subject has dysrhythmia that might pose a risk during exercise or training.
• Subject has resting bradycardia (< 50 beats/min); frequent multifocal PVCs; complex ventricular arrhythmia; sustained SVT.
• Subject has history of exercise-related syncope.
• Subject has uncontrolled hypertension (systolic, > 200 mm; diastolic > 110 mm).
• Subject has history of recurrent infections with clinically significant sputum production
• Subject has known, active asthma, chronic bronchitis or clinically significant bronchiectasis.
• Subject has giant bulla (> 1/3 volume of lung).
• Subject has pulmonary hypertension: peak systolic PPA, ≥ 45 mm Hg (Denver criterion: ≥ 50 mm Hg) or mean PPA, ≥ 35 mm Hg (Denver criterion: ≥ 38 mm Hg). (Right heart catheter is required to rule out pulmonary hypertension if peak systolic PPA on echocardiogram is ≥ 45 mm Hg.)
• Subject has requirement for > 6 L O2 to keep saturation ≥ 90% with exercise.
• Subject has evidence of systemic disease or neoplasia expected to compromise survival during the 1-year study period.
• Subject demonstrates 6MWT distance ≤ 140 m after rehabilitation.
• Subject has any disease or condition that interferes with completion of initial or follow-up assessments.
• Subject has demonstrated unwillingness or inability to complete screening or baseline data collection procedures.
• Subject has only the homogeneous emphysema pattern.
• Subject is classified as ASA Class greater than P4 7 including presence of co-morbidity that could significantly increase the risk of a standard bronchoscopy procedure.

Where it is running

• University of Alabama — Birmingham, Alabama, United States
• Mayo Clinic — Scottsdale, Arizona, United States
• Cedars-Sinai Medical Center — Los Angeles, California, United States
• Emory Health Care — Atlanta, Georgia, United States
• Indiana University — Indianapolis, Indiana, United States
• Lahey Clinic — Burlington, Massachusetts, United States
• North Shore - Long Island Jewish Health System — Long Island City, New York, United States
• Columbia University Medical Center — New York, New York, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Cleveland Clinic Foundation — Cleveland, Ohio, United States
• The Ohio State University — Columbus, Ohio, United States
• University of Pennsylvania Medical Center — Philadelphia, Pennsylvania, United States
• University of Virginia Health System — Charlottesville, Virginia, United States
• University of Washington Medical Center — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.